Navigation Links
NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
Date:3/19/2009
59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights
'/>"/>
| SOURCE DATATRAK International, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
2. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
3. The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo
4. Pharmacyclics Receives Nasdaq Notification
5. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
6. Cell Therapeutics to Resume Trading on MTA and NASDAQ
7. The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders
8. EngagementHealth(R) Launches Comprehensive Wellness Programs With Rurban Financial Corp. (Nasdaq - RBNF)
9. Alfacell Announces Receipt of NASDAQ Panel Decision
10. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
11. NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance
Post Your Comments:
(Date:6/19/2013)... 19, 2013 The deadline to ... this Friday, June 21 at midnight ET. This ... and innovative people who’ve raised the bar on ... http://www.minonline.com/ima . , Any consumer and b2b ... is eligible to enter. Additionally, advertising agencies and ...
(Date:6/19/2013)... Lake City, UT (PRWEB) June 19, 2013 ... companies : , In July 2013, Orriant is ... their participation rates, and maintain compliance with regulations. ... allowing employees to receive wellness incentives if their ... has announced they have been compliant with these ...
(Date:6/19/2013)... Amber Roberson with the Robert ... Native Care Health, LLC and Medcase, LLC, became ... (NAHU) new professional development course on the Patient ... education course for agents has been approved in ... education credits from the Missouri Department of Insurance. ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 According to ... for Surviving Weekend Sunburn,” it is not uncommon for a ... the summer months. A person is likely to forget to ... , which is both dry and itchy. When this occurs, ... (Go to goo.gl/gDyjP). , “Most people do not realize that ...
(Date:6/19/2013)... international study led by researchers at The University of ... continues to show remarkable promise for the treatment of ... most recent interim findings of the 18-center Phase 2 ... Journal of Medicine . Previous interim findings were presented ... Hematology Annual Meeting and Exposition. , Unprecedented ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Skin Care – How to treat Sunburn 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2[0] Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21[0] New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations[0] RWI Benefits, LLC Becomes PPACA Certified[0] Skin Care – How to treat Sunburn[0] Ibrutinib continues strong showing against mantle cell lymphoma
... alert in India's northeast asking authorities to take ... outbreak in Bangladesh and Myanmar, officials said ... Tripura government has made arrangements for free consultation ... sub-divisions, especially those along the bordering areas," Tripura's ...
... known as a poison that can kill, arsenic also can ... leukemia , a new study out Saturday found. ... we give (arsenic) earlier in the course of treatment," said ... in North Carolina, and the lead author of the research ...
... issue of JAMA, has identified novel genetic mutations linked ... these mutations are due to both independent mutational events ... to coincide with its presentation at the annual meeting ... ,According to background information in the article, gastric cancer ...
... CHICAGO, According to a University of Pittsburgh Medical Center ... American Society of Clinical Oncology (ASCO) in Chicago and ... patients treated for follicular lymphoma, a slow-growing type of ... ,Over 90 percent of study patients responded ...
... CEGE) today announced follow-up data from a Phase 2 ... was conducted by the Johns Hopkins Sidney Kimmel Cancer ... pancreatic cancer who received GVAX after surgical resection of ... overall survival for these patients was previously reported to ...
... receiving end, even if it is all subtle, as in ... to pin down is more dangerous to mental health ... immigrants living in Canada. ,"We found that the ... distress such as symptoms of depression and anxiety," said lead ...
Cached Medicine News:Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 2Health News:Researchers Identify Genetic Mutations for Hereditary Diffuse Gastric Cancer 3Health News:Lymphoma Patients Maybe Helped by Adding Radioimmunotherapy to Chemo 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 3Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 4Health News:Koreans in Canada Feel Put Down by Subtle Racism 2Smallpox Alert in NortheastArsenic Poison can Make Longer Life of Leukemia PatientsResearchers Identify Genetic Mutations for Hereditary Diffuse Gastric CancerLymphoma Patients Maybe Helped by Adding Radioimmunotherapy to ChemoCell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic CancerKoreans in Canada Feel Put Down by Subtle Racism
(Date:6/19/2013)... 2013 Nektar Therapeutics (Nasdaq: NKTR ... liability (HAL) study for NKTR-181, a first-in-class, opioid ... brain. This slow rate of entry is designed to reduce ... addiction to current opioid analgesics. 1 In the study ... to placebo in "drug liking" and "feeling high" scores and ...
(Date:6/19/2013)... Calif. , June 19, 2013 BD Biosciences, ... BDX ), a leading global medical technology company, today ... Analyzer , the latest in its line of high-performance research ... Analyzer delivers high-performance multicolor analysis with the most compact footprint ... 73.7 cm) and a height of 30" (76.2 cm). Recognizing ...
(Date:6/19/2013)... ZIONA, Israel , June ... announced that results from a phase I study in ... in advanced Parkinson,s patients, of ND0612, were presented at ... Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug formula ... delivery patch that would maintain constant levodopa plasma concentrations. ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6[0] Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence[0] New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research[0] NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease
... ARBOR, Mich., Nov. 11, 2011 Adeona ... developer of innovative medicines for serious central nervous system ... estriol), will be utilized in a new Phase II ... cognitive dysfunction observed in female multiple sclerosis (MS) patients. ...
... 11, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... Officer, will be presenting at the Lazard Capital Markets 8th ... New York City. Mr. Bentsur,s presentation is scheduled to take ... A live audio webcast of Mr. Bentsur,s presentation ...
Cached Medicine Technology:Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 2Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 3Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 4Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research 5Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 4.0mm....
Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |